Clinical trials: Movement Abnormalities
Parkinson's Disease
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with…
- Trial name
- PARAISO (NCT07174310)
- Testing
- Prasinezumab
- Where
- 192 sites in United States, Australia and 15 more
- Volunteers
- 900 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
The purpose of this multi-center, randomized, double-blind, parallel-group, 26 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of…
- Trial name
- ALLAY-LID-II (NCT02153632)
- Testing
- amantadine HCl ER
- Where
- 56 sites in United States, Canada and 3 more
- Volunteers
- 135 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson Disease
LRRK2 Mutation and Parkinson's Disease
The Leucine-Rich Repeat Kinase 2 (LRRK2) is implicated in autosomal dominant Parkinson's disease (PKD). An inhibitor for the leucine-rich repeat kinase 2 (LRRK2) is in pre-clinical development for potential use in treating…
- Trial name
- NCT01424475
- Testing
- Healthy, PKD Patients
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parkinson Disease, Healthy
Rapid dEvice Testing pROtocol for Parkinson's Disease
This is an 8 week observational study to evaluate the feasibility of using remote monitoring technologies in future studies of PD.
- Trial name
- RETRO-PD (NCT04675853)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- HealthMode Inc.
Parkinson's Disease
Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)
This study is being done to assess the pharmacokinetics of SCH 900800 in participants with moderate to severe Parkinson's Disease (PD) being treated with L-DOPA.
- Trial name
- NCT01500707
- Testing
- SCH 900800
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease, Dyskinesia, Medication-Induced
Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia
The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia.
- Trial name
- NCT05297201
- Testing
- CPL500036 - low dose, CPL500036 - high dose
- Where
- 16 sites in Poland, Ukraine
- Volunteers
- 105 people
- Sponsor
- Celon Pharma SA
Tardive Dyskinesia
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
- Trial name
- NCT07365462
- Testing
- NBI-1065890
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease using placebo and bromocriptine tablets as…
- Trial name
- NCT02172573
- Testing
- Pramipexole, Bromocriptine
- Volunteers
- 315 people
- Sponsor
- Boehringer Ingelheim
Wilson Disease
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease (WD).
- Trial name
- NCT05047523
- Testing
- ALXN1840, Standard of Care
- Where
- 20 sites in Australia, France and 5 more
- Volunteers
- 40 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Parkinson Disease
Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life
The study will compare the effect of pramipexole on different types of tremor and particularly kinetic tremor in early and advanced Parkinson's disease patients and will evaluate the course of tremor measured with spiralometry…
- Trial name
- NCT01100073
- Where
- 215 sites in Estonia, Latvia and 6 more
- Volunteers
- 1,703 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease, Restless Leg Syndrome
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole Tablets, 0.25 mg to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fasting conditions using a single-dose, randomized, 2-treatment…
- Trial name
- NCT00673088
- Testing
- Ropinirole Hydrochloride
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Sleep Disorders
Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
The purpose of this study is to establish the efficacy and safety of Circadin in children with neurodevelopmental disorders and to determine the dose, this randomized, placebo-controlled study is planned to evaluate the efficacy…
- Trial name
- NCT01906866
- Testing
- Circadin 2/5/10 mg
- Where
- 28 sites in United States, Finland and 3 more
- Volunteers
- 125 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Parkinson Disease, Deep Brain Stimulation
Validation of HaGuide Software Module Accuracy in Mapping STN Boundaries in Parkinson's Disease Patients Who Underwent DBS Procedure
HaGuide version 1.0 (Neuro-Omega Ltd.) is a software module add-on to the FDA cleared Neuro-Omega System (K123796). It was designed to facilitate the use of Neuro-Omega's system by automatically mapping visually the depth of STN…
- Trial name
- NCT03363724
- Testing
- HaGuide version 1.0 software module
- Volunteers
- 103 people
- Sponsor
- Alpha Omega Engineering Ltd.
Dyskinesias, Parkinson Disease
Effects of Talampanel on Patients With Advanced Parkinson's Disease
The purpose of this research study is to test the safety and effectiveness of the study drug, Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to Parkinson's…
- Conditions
- Dyskinesias, Parkinson Disease, Movement Disorders
- Trial name
- NCT00036296
- Testing
- talampanel
- Volunteers
- 22 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson's Disease
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
The study had three distinct parts and is described as follows: Part 1: To evaluate the dose conversion from CD-LD ER taken alone or in combination with CD-LD IR to IPX066 in subjects with advanced PD To evaluate the utility of…
- Trial name
- NCT01411137
- Testing
- IPX066
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Impax Laboratories, LLC
Parkinson's Disease (PD)
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) monotherapy in a routine clinical setting.
- Trial name
- COSMOS (NCT03362879)
- Where
- 30 sites in Austria, Canada and 9 more
- Volunteers
- 412 people
- Sponsor
- AbbVie
Parkinson Disease
A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease
This prospective, randomized, multicenter study aims to evaluate in Early-Stage Parkinson's Disease (ESPD) patients the safety and effectiveness of treatment with Exablate MRgFUS subthalamotomy vs best medical treatment.
- Trial name
- NCT06584383
- Testing
- Exablate MRgFUS subthalamotomy, Best Medical Treatment
- Where
- 4 sites in Chile, Germany and 1 more
- Volunteers
- 67 people
- Sponsor
- InSightec
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Parkinson's Disease
Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)
A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS).
- Trial name
- CONFIDENT-PD (NCT01060878)
- Testing
- PYM50028
- Where
- 111 sites in United States, Canada and 8 more
- Volunteers
- 425 people
- Sponsor
- Phytopharm
Parkinson Disease
Fixed-Dose Trial in Early Parkinson's Disease (PD)
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
- Trial name
- TEMPO-1 (NCT04201093)
- Testing
- Tavapadon
- Where
- 77 sites in United States, Australia and 10 more
- Volunteers
- 529 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.